Data Management And Sharing System of China National Clinical Research Center for Neurological Diseases
m(6)A RNA methylation regulators contribute to malignant progression and have clinical prognostic impact in gliomas
First author：Chai Rui-Chao,Wu Fan,Wang Qi-Xue
Corresponding author：Wang Yong-Zhi,Kang Chun-Sheng
essential_information
- Person in charge：Chai Rui-Chao,Wu Fan,Wang Qi-Xue
- Data Sources： OTHERS
- Number of papers：OTHERS20190783
- Published time：2019-02-27
2019-02-27
Published articles
Journal：Aging
Publication type: Research Paper
IF(IF): 5.515
PMID: 30810537 Link To Pubmed Full text Download
Background And Purpose
Method
Here, we demonstrate that most of the thirteen main m6A RNA methylation regulators are differentially expressed among gliomas stratified by different clinicopathological features in 904 gliomas. We identified two subgroups of gliomas (RM1/2) by applying consensus clustering to m6A RNA methylation regulators. Compared with the RM1 subgroup, the RM2 subgroup correlates with a poorer prognosis, higher WHO grade, and lower frequency of IDH mutation. Moreover, the hallmarks of epithelial-mesenchymal transition and TNFα signaling via NF-κB are also significantly enriched in the RM2 subgroup.
Conclusion
In conclusion, m6A RNA methylation regulators are crucial participants in the malignant progression of gliomas and are potentially useful for prognostic stratification and treatment strategy development.
Main results
This finding indicates that m6A RNA methylation regulators are closely associated with glioma malignancy. Based on this finding, we derived a risk signature, using seven m6A RNA methylation regulators, that is not only an independent prognostic marker but can also predict the clinicopathological features of gliomas. Moreover, m6A regulators are associated with the mesenchymal subtype and TMZ sensitivity in GBM.